NASH: The Next Frontier Nonalcoholic steatohepatitis, simply put, is lots of fat in the liver with enough inflammation to to cause scarring (cirrhosis) and eventual liver failure. NASH is a leading cause of liver mortality in the United States. Nonalcoholic steatohepatitis is a more advanced form of nonalcoholic fatty liver disease (NAFLD). Most patients are obese …
One stop shopping: lillydirect.lilly.com One stop shopping with a little hooker!Yes an online visit with the doctor for the ok and the prescription. ($) Yes patients who are prescribed Zepbound will be eligible for Lilly’s at-home prescription delivery service connected with Form Health providers. ($) No discount off retail unless you qualify for insurance coverage or …
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). The 15.6% mean weight loss observed with the 2.4 mg dose was associated with a mean weight loss of 32.2 lbs at 48 weeks. 48% of subjects …
Semaglutide meds work, especially Ozempic, Wegovy and Zepbound. We are now talking about real weight loss for the first time. And we recognize obesity and the associated obesity comorbidities represent CHRONIC disease. So ultimately, how effective are the new semaglutide meds treating obesity and associated diseases. Data is beginning to provide some insight for effectiveness …
Medicare Today—- The data: About 40% of the nearly 66 million people enrolled in Medicare are obese. The good news: Medicare will cover obesity screening and behavioral treatment if a person has body mass index over 30. Medicare does cover certain surgical procedures to treat medical complications of obesity in people with a body mass …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes(NEJM December 14, 2023) It is clear that semaglutide medications improve the outcomes some of the cardiovascular outcomes of obese type 2 diabetics. It now appears that this is also true for those with obesity and existing cardiovascular disease (at least for 2.4 mg weekly for 48 weeks).In …
New Kids that Don’t Grow Up: The Biotech War for weight loss drugs is heating up: Altimmune stepped into the ring and got knocked down with a first round knockout. In a Phase 2 trial, patients lost an average of about 9% and 11%, respectively, of their body weight after six months of treatment. But …
Tirzepatide: The New Kid On The Block It’s not really a new kid on the block, but rather a new FDA indication. Just as Ozempic (marketed for type 2 diabetes) and Wegovy (marketed for weight loss) are identical semaglutide drugs we now have Mounjaro (marketed for type 2 diabetes) and Zepbound (marketed for weight loss) …
Adverse Events : So you are considering starting a GLP-1 agonist. Perhaps you qualify for a Lilly or Novo discount (starter 1-3 months). Or you are willing to pay the high monthly price and have obtained a prescription. And finally you can find it at a reputable pharmacy (FDA approved) but are concerned about the …
Semaglutide Knockoffs : Let’s remember Ozempic, Wegovy, Mounjaro and Zepbound are all compounded for injections. They are also chronically in short supply and extremely expensive. So it is no surprise that illicit knockoffs as well as dangerous ingredients (salts) are on the market. Here is a history of some compounding disasters: In 2012, a fungal …
WeightWatchers Switch: Oprah Comes out of the Closet ! Keeping up with the times! Weight Watchers is now WW. Reading the tea leaves and the sudden evolution of the weight loss industry, WW has purchased the telehealth platform Sequence to prescribe on line and support the use of semaglutide medications. This just demonstrates the game …
Semaglutide and Heart Failure It’s more than just weight loss: Patients that were obese (BMI>30) with heart failure (well preserved ejection fraction) were evaluated over 52 weeks while treated with once weekly semaglutide or placebo. Decreases in the CRP level, systolic blood pressure, and NT-proBNP level were also greater in the semaglutide group than in the …
